FULGENT PHARMA Trademark

Trademark Overview

On Friday, March 3, 2023, a trademark application was filed for FULGENT PHARMA with the United States Patent and Trademark Office. The USPTO has given the FULGENT PHARMA trademark a serial number of 97822517. The federal status of this trademark filing is REGISTERED as of Tuesday, October 21, 2025. This trademark is owned by Fulgent Genetics, Inc.. The FULGENT PHARMA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs; medicinal preparations for treating cancer, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs

Medical research in the field of oncology; clinical research in the field of oncology; pharmaceutical research and development in the field of oncology; research and development in the pharmaceutical and biotechnology fields; pharmaceutical drug development services; medical research, namely, research of nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs
fulgent pharma

General Information

Serial Number97822517
Word MarkFULGENT PHARMA
Filing DateFriday, March 3, 2023
Status700 - REGISTERED
Status DateTuesday, October 21, 2025
Registration Number7995377
Registration DateTuesday, October 21, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs; medicinal preparations for treating cancer, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs
Goods and ServicesMedical research in the field of oncology; clinical research in the field of oncology; pharmaceutical research and development in the field of oncology; research and development in the pharmaceutical and biotechnology fields; pharmaceutical drug development services; medical research, namely, research of nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs
NOT AVAILABLE"PHARMA"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code005
First Use Anywhere DateWednesday, April 23, 2025
First Use In Commerce DateWednesday, April 23, 2025
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code042
First Use Anywhere DateTuesday, November 1, 2022
First Use In Commerce DateTuesday, November 1, 2022

Trademark Owner History

Party NameFulgent Genetics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressEl Monte, CA 91731
Party NameFulgent Genetics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEl Monte, CA 91731
Party NameFulgent Genetics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTemple City, CA 91780

Trademark Events

Event DateEvent Description
Tuesday, March 7, 2023NEW APPLICATION ENTERED
Thursday, March 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 16, 2023ASSIGNED TO EXAMINER
Tuesday, October 17, 2023NON-FINAL ACTION WRITTEN
Tuesday, October 17, 2023NON-FINAL ACTION E-MAILED
Tuesday, October 17, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 3, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, January 3, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, January 30, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 7, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 30, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 30, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 30, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 30, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 19, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, September 19, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 19, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 31, 2024SOU TEAS EXTENSION RECEIVED
Thursday, October 31, 2024SOU EXTENSION 1 FILED
Thursday, October 31, 2024SOU EXTENSION 1 GRANTED
Thursday, October 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 1, 2025TEAS STATEMENT OF USE RECEIVED
Wednesday, June 4, 2025ASSIGNED TO EXAMINER
Wednesday, June 4, 2025ASSIGNED TO EXAMINER
Saturday, September 27, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 1, 2025USE AMENDMENT FILED
Saturday, September 27, 2025STATEMENT OF USE PROCESSING COMPLETE
Tuesday, September 30, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 30, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 21, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, October 21, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, November 12, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 12, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 12, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 12, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 12, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 12, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

Related Keywords

pharma fulgent drugs research oncology pharmaceutical based molecule development small field immuno